Jose G. Guillem, MD, MPH | Authors

Nonoperative Strategies for Rectal Cancer Following a Complete Clinical Response to Preoperative Chemoradiation: A Few Considerations

July 15, 2014

Although the current standard treatment for patients with locally advanced rectal cancer is preoperative chemoradiotherapy followed by total mesorectal excision, concerns have been raised over the functional sequelae and possible overtreatment of rectal cancer patients.

Have the Changes in Treatment of Rectal Cancer Made a Significant Difference to Our Patients?

December 15, 2011

Treatment for patients with locally advanced, resectable rectal cancer has clearly evolved, with significant refinements in preoperative assessment, surgical technique, and use of preoperative chemoradiation.

Multidisciplinary Management of Resectable Rectal Cancer

November 16, 2008

Prior to the publication of the German CAO/ARO/AIO 94 trial, the conventional adjuvant approach for patients with clinically resectable, ultrasonographically diagnosed T3 (uT3) and/or node-positive rectal cancer was initial surgery and, if pathologically confirmed T3 (pT3) and/or node-positive, postoperative combined chemotherapy plus radiation. The German trial confirmed that compared to postoperative therapy, the preoperative approach was associated with significantly lower local recurrence rates, less acute and chronic toxicity, and an increased incidence of sphincter preservation.